Home / Stocks / Astrazeneca Pharma Ind Lt
ASTRAZEN

Astrazeneca Pharma Ind Lt Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹6,113.0

Change

+69.5 (1.15%)

Open

₹6,023.5

Prev. Close

₹6,043.5

Day High

₹6,148.5

Day Low

₹5,994.5

Volume Analysis

Traded

11,322

Delivered

6,345

Delivery %

56.04%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (23.6%)
  • •Strong 3-year revenue growth (31.4%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹6,330.16 ₹6,239.33 ₹6,176.16 ₹6,085.33 ₹6,022.16 ₹5,931.33 ₹5,868.16
Fibonacci ₹6,239.33 ₹6,180.5 ₹6,144.16 ₹6,085.33 ₹6,026.5 ₹5,990.16 ₹5,931.33
Camarilla ₹6,155.35 ₹6,141.23 ₹6,127.12 ₹6,085.33 ₹6,098.88 ₹6,084.77 ₹6,070.65

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-30.36%

1 Week

-5.06%

1 Month

+0.55%

3 Months

-17.56%

6 Months

-28.82%

1 Year

-33.07%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

21.39%

Net margin 8.26% × asset turnover 1.04x × equity multiplier 2.49x

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Astrazeneca Pharma Ind Lt holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 67/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Strong 3-year EPS growth (23.6%).

TopFund Score — Fundamentals Quality

67/100 — Good

Data confidence: 73/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

93

Cash Flow

0

Corporate Governance

90

Institutional Ownership

47

Business Quality

59

Risk & Volatility

58

Liquidity

60

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

AstraZeneca India signed an LOI with Strand Life Sciences on November 17, 2026 to explore healthcare collaboration.

AstraZeneca India signed LOI with Strand Life Sciences on November 17, 2026 to explore healthcare collaboration in India.

AstraZeneca Pharma India will launch Datopotamab Deruxtecan (Datverzo) in India in November 2026.

AstraZeneca may receive revised Bengaluru improvement charges notice; likely amount up to INR 70.8 million plus interest.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026 (S)
Sales + 311 306 383 388 408 440 480 526 559 612 579 683 729
Expenses + 258 291 334 349 355 363 394 445 484 567 518 634 634
Operating Profit 53 15 49 38 53 77 86 81 75 45 61 49 96
OPM % 17.0% 4.9% 13.0% 10.0% 13.0% 17.0% 18.0% 15.0% 13.0% 7.0% 11.0% 7.0% 13.0%
Other Income + 25 10 9 -49 8 -26 10 11 1 7 5 9 0
Interest 0 1 0 0 0 0 1 1 1 1 2 2 2
Depreciation 4 4 4 4 9 9 18 17 3 4 6 5 5
Profit before tax 73 20 54 -15 51 42 78 75 73 47 58 51 88
Tax % 29.0% 23.0% 27.0% -22.0% 25.0% 27.0% 26.0% 25.0% 26.0% 30.0% 23.0% 25.0% 30.0%
Net Profit + 52 16 39 -12 38 31 58 56 54 33 45 38 62
EPS in Rs 21 6 16 -5 15 12 23 22 22 13 18 15 25
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 32 22 35 31 31 44 25 36 37 39 20 30 30

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Sales + 517 564 544 571 728 832 814 806 1,003 1,296 1,716 2,276
Expenses + 528 547 506 525 657 711 678 719 838 1,111 1,462 2,014
Operating Profit -11 16 37 46 71 121 135 86 165 184 254 262
OPM % -2.2% 2.9% 7.0% 8.0% 10.0% 15.0% 17.0% 11.0% 16.0% 14.0% 15.0% 12.0%
Other Income + 6 7 14 12 16 13 13 15 -14 51 -56 23
Interest 0 0 0 0 0 1 1 1 1 1 1 4
Depreciation 15 17 16 15 15 19 20 17 16 15 40 29
Profit before tax -21 6 36 44 73 114 127 83 134 220 156 252
Tax % 0.0% 9.0% 44.0% 41.0% 25.0% 37.0% 27.0% 26.0% 26.0% 26.0% 26.0% 26.0%
Net Profit + -21 5 20 26 54 72 93 62 99 162 116 188
EPS in Rs -8 2 8 10 22 29 37 25 40 65 46 75
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 3.0% 5.0% 41.0% 40.0% 37.0% 69.0% 48.0%
Sales growth 9 9 -4 5 28 14 -2 -1 24 29 32 33

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S) Sep 2026 (S)
Reserves 146 151 218 242 296 359 451 506 584 707 765 868 874
Borrowings + 0 0 0 0 0 12 12 9 7 5 36 111 96
Other Liabilities + 261 247 193 214 261 330 306 337 389 362 712 1,006 1,216
Total Liabilities 412 403 415 461 562 706 775 857 985 1,078 1,518 1,989 2,191
Fixed Assets + 101 97 87 75 75 72 81 74 69 67 64 117 99
CWIP 12 6 5 4 7 24 4 2 1 0 0 0 16
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Assets + 298 299 324 382 480 611 690 780 915 1,011 1,454 1,872 2,077
Total Assets 412 403 415 461 562 706 775 857 985 1,078 1,518 1,989 2,191
Equity Capital 5 5 5 5 5 5 5 5 5 5 5 5 5

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Cash from Operating Activity + -46 57 38 9 55 87 105 101 58 28 65 -15
Cash from Investing Activity + -19 -4 0 -9 4 -171 173 5 18 22 31 19
Cash from Financing Activity + 0 -1 0 0 0 -6 -9 -9 -24 -44 -66 -92
Net Cash Flow -64 53 38 -1 59 -90 269 96 52 5 31 -88
Free Cash Flow -69 48 33 3 37 74 99 94 53 18 64 -18
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 393 365 133 28 126 100 101 146 60 46 51 26

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 75.0% → 75.0%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 19.57% 18.5% 17.21% 17.02% 16.85% 17.45% 17.41% 17.0% 16.73% 16.42% 16.24% 15.27%
Promoters 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0%
FII 2.66% 2.73% 2.79% 2.9% 2.92% 2.89% 3.03% 2.74% 2.71% 2.78% 2.68% 2.64%
DII 2.76% 3.77% 4.99% 5.08% 5.21% 4.65% 4.55% 5.26% 5.55% 5.79% 6.08% 7.09%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Astrazeneca Pharma Ind Lt (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Astrazeneca Pharma Ind Lt?

Frequently Asked Questions about Astrazeneca Pharma Ind Lt

Community Sentiment

What are other investors saying about Astrazeneca Pharma Ind Lt?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.